Biopharma · FDA Approvals · Stock

TPST Tempest Therapeutics

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage …

Assets on file: BCMA/GPRC5D dual-targeting in vivo CAR-T, TPST-2003

Start live analysis of TPST Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for TPST, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for TPST, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Sep 17, 2026

09:05 PM

TPSTTempest Therapeutics, Inc.

Tempest Therapeutics Secures Exclusive Option to License Senlang's CD7 Lentiviral In Vivo CAR-T Platform

Tempest obtained an exclusive option to license Senlang's CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T candidates, including a BCMA/GPRC5D dual-targeting program in Phase 1 for r/r multiple myeloma. Early Phase 1 data show in vivo CAR-T generation/expansion and a favorable initial safety profile supporting dose escalation. The deal complements Tempest's existing CD7-targeted LNP platform planned for clinic entry later in 2026.

Partnership / licensing dealSEC 8-K Open record

May 14, 2026

08:28 PM

TPSTTempest Therapeutics, Inc.

Tempest reports 100% CR rate for TPST-2003 in rrMM

The 8-K reports positive interim Phase 1/2a data from REDEEM-1 and POEMS-1 trials showing a 100% complete response rate in all 15 CAR-T-naïve efficacy-evaluable patients treated with TPST-2003. The data also highlight a favorable safety profile with no Grade ≥3 CRS or ICANS and prior median PFS of 23.1 months. These results support the planned initiation of a U.S. registrational study later this year.

Topline resultsSEC 8-K Open record1 update